Open AccessRanolazine for Congenital and Acquired Late I Na -Linked Arrhythmias
Author(s) -
Jonathan D. Moreno,
PeiChi Yang,
John R. Bankston,
Eleonora Grandi,
Donald M. Bers,
Robert S. Kass,
Colleen E. Clancy
Publication year - 2013
Publication title -
circulation research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.899
H-Index - 336
eISSN - 1524-4571
pISSN - 0009-7330
DOI - 10.1161/circresaha.113.301971
Subject(s) - ranolazine , qt interval , long qt syndrome , medicine , heart failure , cardiology , repolarization , blockade , sodium channel blocker , pharmacology , proarrhythmia , sodium channel , chemistry , receptor , electrophysiology , sodium , organic chemistry
The antianginal ranolazine blocks the human ether-a-go-go-related gene-based current IKr at therapeutic concentrations and causes QT interval prolongation. Thus, ranolazine is contraindicated for patients with preexisting long-QT and those with repolarization abnormalities. However, with its preferential targeting of late INa (INaL), patients with disease resulting from increased INaL from inherited defects (eg, long-QT syndrome type 3 or disease-induced electric remodeling (eg, ischemic heart failure) might be exactly the ones to benefit most from the presumed antiarrhythmic properties of ranolazine.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom